Fortis Capital Management’s iShares iBonds Dec 2028 Term Corporate ETF IBDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.2M Buy
87,159
+19,420
+29% +$490K 0.25% 69
2026
Q1
$1.72M Sell
67,739
-413
-0.6% -$10.5K 0.18% 69
2025
Q4
$1.73M Buy
68,152
+538
+0.8% +$13.7K 0.23% 64
2025
Q3
$1.73M Buy
67,614
+5,293
+8% +$135K 0.24% 63
2025
Q2
$1.58M Sell
62,321
-7,856
-11% -$198K 0.25% 65
2025
Q1
$1.77M Buy
70,177
+14,146
+25% +$354K 0.34% 59
2024
Q4
$1.4M Sell
56,031
-20,996
-27% -$527K 0.26% 67
2024
Q3
$1.97M Buy
77,027
+7,235
+10% +$182K 0.4% 56
2024
Q2
$1.73M Buy
69,792
+9,758
+16% +$241K 0.37% 54
2024
Q1
$1.5M Sell
60,034
-7,682
-11% -$191K 0.39% 56
2023
Q4
$1.7M Buy
67,716
+47,050
+228% +$1.14M 0.43% 47
2023
Q3
$497K Buy
+20,666
New +$503K 0.15% 95

Other funds holding IBDT

Fortis Capital Management's IBDT Position: Q2 2026 in Review

Fortis Capital Management increased its iShares iBonds Dec 2028 Term Corporate ETF (IBDT) stake by 29% in Q2 2026, buying an estimated $490K and bringing the position to 87,159 shares worth $2.2M. The position accounts for 0.25% of the portfolio, ranked #69.

Fortis Capital Management first reported a position in IBDT in Q3 2023 and has held it in 12 quarters since. 435 funds tracked by Wall St. Rank hold IBDT as of Q2 2026.

  • Fortis Capital Management held 87,159 shares of iShares iBonds Dec 2028 Term Corporate ETF worth $2.2M as of Q2 2026.
  • Fortis Capital Management bought 19,420 iShares iBonds Dec 2028 Term Corporate ETF shares in Q2 2026, an estimated $490K.
  • iShares iBonds Dec 2028 Term Corporate ETF made up 0.25% of Fortis Capital Management's portfolio in Q2 2026, its #69 holding.
  • Fortis Capital Management first reported a position in iShares iBonds Dec 2028 Term Corporate ETF in Q3 2023 and has held it in 12 quarters since.
  • 435 funds tracked by Wall St. Rank held iShares iBonds Dec 2028 Term Corporate ETF as of Q2 2026.

Based on Fortis Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.